AU2002313811A1 - Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease - Google Patents

Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Info

Publication number
AU2002313811A1
AU2002313811A1 AU2002313811A AU2002313811A AU2002313811A1 AU 2002313811 A1 AU2002313811 A1 AU 2002313811A1 AU 2002313811 A AU2002313811 A AU 2002313811A AU 2002313811 A AU2002313811 A AU 2002313811A AU 2002313811 A1 AU2002313811 A1 AU 2002313811A1
Authority
AU
Australia
Prior art keywords
cd40r
alzheimer
disruption
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002313811A
Inventor
Michael Mullan
Jun Tan
Terrence C. Town
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Priority claimed from PCT/US2002/027035 external-priority patent/WO2003014328A2/en
Publication of AU2002313811A1 publication Critical patent/AU2002313811A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002313811A 2001-08-10 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease Abandoned AU2002313811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31111501P 2001-08-10 2001-08-10
US60/311,115 2001-08-10
PCT/US2002/027035 WO2003014328A2 (en) 1999-06-01 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2002313811A1 true AU2002313811A1 (en) 2003-02-24

Family

ID=32298094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313811A Abandoned AU2002313811A1 (en) 2001-08-10 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Country Status (3)

Country Link
EP (1) EP1423144A4 (en)
AU (1) AU2002313811A1 (en)
CA (1) CA2467919A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023590A2 (en) * 1998-10-20 2000-04-27 Georgetown University Medical Center INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
ATE325874T1 (en) * 2000-06-09 2006-06-15 Biogen Idec Inc CD154 VARIANTS AND THEIR USE

Also Published As

Publication number Publication date
EP1423144A4 (en) 2006-08-02
EP1423144A2 (en) 2004-06-02
CA2467919A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2003284968A1 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002319615A1 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2002303957A1 (en) Method of treating alzheimer's disease with se-containing peptide
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002313811A1 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU2003230848A1 (en) Methods and compositions for treating alzheimer's disease
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase